Designer glycopeptides for cytotoxic T cell-based elimination of carcinomas

Area of Science:

• Immunology
• Glycobiology
• Oncology

Background:

• Tumors express unique embryonic carbohydrate structures known as tumor-associated carbohydrate antigens (TACA).
• TACA-based glycopeptides are promising candidates for cancer vaccines due to their presence across various tumor types.
• Cytotoxic T lymphocyte (CTL)-based vaccines offer a strategy for widespread cancer prevention and treatment.

Purpose of the Study:

• To investigate the immunogenicity of designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen.
• To determine if these glycopeptides can induce TACA-specific CTL responses in vivo.
• To assess the potential of TF-specific CTLs in recognizing and targeting tumor cells.

Main Methods:

• Synthesis of designer glycopeptides with high affinity for major histocompatibility complex (MHC) molecules.
• Glycosylation at a critical T cell receptor (TcR) contact position.
• In vivo induction of anti-TACA CTL responses.
• In vitro assessment of TF-specific CTL recognition of tumor cells, including MUC1-expressing tumors.

Main Results:

• Designer TF-antigen glycopeptides were found to be immunogenic in vivo.
• TF-specific CTLs were generated, capable of recognizing various tumor cells.
• CTL recognition occurred in a conventional MHC class I-restricted manner, with TcR recognizing the glycosylated residue and TF antigen.
• Demonstrated recognition of MUC1-expressing tumor cells by TF-specific CTLs.

Conclusions:

• Designer glycopeptides targeting TACA, specifically the TF antigen, can effectively induce anti-TACA CTL responses.
• This approach holds significant potential for developing broad-spectrum cancer immunotherapies.
• The findings support the use of glycopeptides in cancer vaccines for targeting a wide range of tumors.